A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer

被引：0
|
作者：
Yoshino, T. [1 ]
Siena, S. [2 ]
Dalal, R. [3 ]
Okuda, Y. [4 ]
Yamamoto, E. [5 ]
Grothey, A. [6 ]
机构：
[1] Natl Canc Ctr Hosp East, Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[2] Univ Milan, Niguarda Canc Ctr, Milan, Italy
[3] Daiichi Sankyo Inc, Med, Basking Ridge, NJ USA
[4] Daiichi Sankyo Co Ltd, Biostat & Data Management Dept, Chuo Ku, Tokyo, Japan
[5] Daiichi Sankyo Co Ltd, Clin Dev, Chuo Ku, Tokyo, Japan
[6] Mayo Clin, Canc Ctr, Dept Med Oncol, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
146TiP
引用
收藏
页码：45 / 45
页数：1
相关论文
共 50 条
  • [41] A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
    Iwata, Tomomi Nakayama
    Ishii, Chiaki
    Ishida, Saori
    Ogitani, Yusuke
    Wada, Teiji
    Agatsuma, Toshinori
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (07) : 1494 - 1503
  • [42] Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE trial, NCCH1615): A multicenter, phase II clinical trial
    Hasegawa, K.
    Nishikawa, T.
    Hirakawa, A.
    Kawasaki, M.
    Tomatsuri, S.
    Nagasaka, Y.
    Nakamura, K.
    Matsumoto, K.
    Mori, M.
    Hirashima, Y.
    Takehara, K.
    Ariyoshi, K.
    Kato, T.
    Yagishita, S.
    Hamada, A.
    Yoshida, H.
    Yonemori, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S767 - S767
  • [43] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study (vol 20, pg 816, 2019)
    Tamura, K.
    Tsurutani, J.
    Takahashi, S.
    LANCET ONCOLOGY, 2019, 20 (06): : E293 - E293
  • [44] Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys
    Nagai, Yoko
    Oitate, Masataka
    Shiozawa, Hideyuki
    Ando, Osamu
    XENOBIOTICA, 2019, 49 (09) : 1086 - 1096
  • [45] Trastuzumab and capecitabine in patients with HER2-expressing metastatic pancreatic cancer: A multicenter phase II study of the German AIO Pancreatic Cancer Group (AIO PK-0204)
    Geissler, M.
    Hofheinz, R.
    Moehler, M. H.
    Bitzer, M.
    Boeck, S. H.
    Reinacher-Schick, A.
    Heinemann, V.
    Harder, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer
    Lazaratos, Anna-Maria
    Petrecca, Kevin
    Guiot, Marie-Christine
    Dankner, Matthew
    Jerzak, Katarzyna J.
    LANCET ONCOLOGY, 2024, 25 (07): : e282 - e282
  • [47] Safety and efficacy results from a phase 1 study of DS-8201a in patients with HER2 expressing breast cancers
    Modi, Shamu
    Tsurutani, Junji
    Takahashi, Shunji
    Iwata, Hiroji
    Park, Haeseong
    Redfern, Charles H.
    Doi, Toshihiko
    Li, Bob
    Iwasa, Tsutomu
    Taira, Shunichiro
    Hattori, Masaya
    Ma, Cynthia X.
    Fisher, Jennifer M.
    Naito, Yoichi
    Yonemori, Kan
    Kawasaki, Yui
    Saito, Kaku
    Jikoh, Takahiro
    Shahidi, Javad
    Lee, Caleb C.
    Yver, Antoine
    Tamura, Kenji
    CANCER RESEARCH, 2018, 78 (04)
  • [48] Autophagy modulates intracellular dynamics of [fam-]trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)
    Abe, Manabu
    Nagata, Motoko
    Koyama, Kumiko
    Yasuda, Satoru
    Hirata, Tsuyoshi
    Kuwahara, Yusuke
    Inaki, Koichiro
    Kasanuki, Naomi
    Minami, Megumi
    Hagihara, Katsunobu
    Wakita, Kenichi
    Slosberg, Eric
    Murakami, Masato
    CANCER RESEARCH, 2019, 79 (13)
  • [49] Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
    Mutlu, Levent
    McNamara, Blair
    Bellone, Stefania
    Manavella, Diego D.
    Demirkiran, Cem
    Greenman, Michelle
    Verzosa, Miguel Skyler Z.
    Buza, Natalia
    Hui, Pei
    Hartwich, Tobias Max Philipp
    Harold, Justin
    Yang-Hartwich, Yang
    Zipponi, Margherita
    Altwerger, Gary
    Ratner, Elena
    Huang, Gloria S.
    Clark, Mitchell
    Andikyan, Vaagn
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    CLINICAL & EXPERIMENTAL METASTASIS, 2024, 41 (05) : 765 - 775
  • [50] HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
    Siena, Salvatore
    Raghav, Kanwal
    Masuishi, Toshiki
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Elez, Elena
    Rodriguez, Javier
    Chau, Ian
    Di Bartolomeo, Maria
    Kawakami, Hisato
    Suto, Fumitaka
    Koga, Makito
    Inaki, Koichiro
    Kuwahara, Yusuke
    Takehara, Issey
    Barrios, Daniel
    Kobayashi, Kojiro
    Grothey, Axel
    Yoshino, Takayuki
    NATURE COMMUNICATIONS, 2024, 15 (01)
12345